ATE187775T1 - Verfahren zur herstellung von menschlichem serumalbumin in hefe - Google Patents

Verfahren zur herstellung von menschlichem serumalbumin in hefe

Info

Publication number
ATE187775T1
ATE187775T1 AT89402217T AT89402217T ATE187775T1 AT E187775 T1 ATE187775 T1 AT E187775T1 AT 89402217 T AT89402217 T AT 89402217T AT 89402217 T AT89402217 T AT 89402217T AT E187775 T1 ATE187775 T1 AT E187775T1
Authority
AT
Austria
Prior art keywords
yeast
human serum
producing human
serum albumine
albumine
Prior art date
Application number
AT89402217T
Other languages
English (en)
Inventor
Rheinhard Fleer
Hiroshi Fukuhara
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8810615A external-priority patent/FR2635115B1/fr
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Application granted granted Critical
Publication of ATE187775T1 publication Critical patent/ATE187775T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT89402217T 1988-08-05 1989-08-04 Verfahren zur herstellung von menschlichem serumalbumin in hefe ATE187775T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8810615A FR2635115B1 (fr) 1988-08-05 1988-08-05 Procede de preparation de la serum albumine humaine a partir d'une levure
FR898908897A FR2649991B2 (fr) 1988-08-05 1989-07-03 Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces

Publications (1)

Publication Number Publication Date
ATE187775T1 true ATE187775T1 (de) 2000-01-15

Family

ID=26226839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89402217T ATE187775T1 (de) 1988-08-05 1989-08-04 Verfahren zur herstellung von menschlichem serumalbumin in hefe

Country Status (13)

Country Link
EP (1) EP0361991B1 (de)
JP (1) JP3068139B2 (de)
KR (1) KR910004800A (de)
AT (1) ATE187775T1 (de)
AU (1) AU623425B2 (de)
DE (1) DE68929115T2 (de)
DK (1) DK175846B1 (de)
FI (1) FI893702A7 (de)
FR (1) FR2649991B2 (de)
HU (1) HUT51329A (de)
NO (1) NO893149L (de)
NZ (1) NZ230229A (de)
PT (1) PT91381B (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017176A1 (en) * 1989-05-22 1990-11-22 Yoshitomi Pharmaceutical Industries Ltd. Albumin gene-containing plasmid, transformant carrying same, production of such transformant and production of albumin
FR2676070B1 (fr) * 1991-04-30 1994-09-30 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
FR2678636A1 (fr) * 1991-07-02 1993-01-08 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes et cellules hote utilisees.
JPH06501033A (ja) 1991-07-12 1994-01-27 ギスト　ブロカデス　ナムローゼ　フェンノートシャップ 血清アルブミンの精製方法
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
FR2679920A1 (fr) * 1991-08-02 1993-02-05 Rhone Poulenc Rorer Sa Levures recombinantes hautement stables pour la production de proteines recombinantes, leur preparation et leur utilisation.
FR2686620B1 (fr) * 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2693475B1 (fr) * 1992-07-08 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'identification et/ou de clonage de promoteurs transcriptionnels, et utilisation de ces promoteurs pour l'expression de gènes.
FR2693463B1 (fr) * 1992-07-08 1994-09-02 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
FR2693464B1 (fr) * 1992-07-08 1994-09-02 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
FR2694294B1 (fr) * 1992-07-30 1994-09-09 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisateur.
DE4244915C2 (de) * 1992-08-14 1998-12-03 Widmar Prof Dr Tanner DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
CA2136564C (en) * 1993-11-26 2008-04-08 Kaoru Kobayashi Process for producing human serum albumin
CA2157219C (en) * 1994-08-31 2010-10-05 Munehiro Noda Process for purifying recombinant human serum albumin
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
JP2003522154A (ja) † 2000-02-08 2003-07-22 アラーガン、インコーポレイテッド ボツリヌス毒素医薬組成物
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2042196B1 (de) 2001-10-10 2016-07-13 ratiopharm GmbH Neumodellierung und Glykokonjugation von Granulozyten-Kolonie stimulierender Faktor (G-CSF)
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR100441384B1 (ko) * 2002-01-08 2004-07-21 주식회사 안지오랩 인간 혈청 알부민-팀프-2 융합 단백질 발현시스템 및재조합 인간 혈청 알부민-팀프-2 융합 단백질
CA2475382A1 (en) 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
US7517671B2 (en) 2002-02-28 2009-04-14 New England Biolabs, Inc. Methods and compositions for concentrating secreted recombinant protein
CN101172091B (zh) 2007-09-25 2011-04-27 北京美福源生物医药科技有限公司 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
GB0329681D0 (en) * 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CA2695830A1 (en) 2007-08-08 2009-02-12 Novozymes Biopharma Dk A/S Transferrin variants and conjugates
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
EP3381933B1 (de) 2008-06-24 2020-06-03 Technische Universität München Muteine von hngal und verwandte proteine mit affinität für ein gegebenes target
MX2011007583A (es) 2009-01-16 2011-12-14 Teva Pharma Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
AU2010280688A1 (en) 2009-08-05 2012-02-23 Allergan, Inc. Controlled release formulations of lipocalin muteins
EP2510357B1 (de) 2009-12-07 2016-03-30 Pieris AG Muteine von humanem lipocalin 2 (lcn2, hngal) mit affinität für ein bestimmtes zielmolekül
AU2010340358B2 (en) 2009-12-21 2014-07-24 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
CN103154023B (zh) 2010-08-16 2017-04-05 皮里斯制药有限公司 铁调素的结合蛋白
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
EP2646552B1 (de) 2010-12-02 2017-07-05 Pieris Pharmaceuticals GmbH Muteine von menschlichem lipocalin 2 mit affinität für ctla-4
WO2013087660A1 (en) 2011-12-13 2013-06-20 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
US10126304B2 (en) 2013-01-16 2018-11-13 George Mason Research Foundation, Inc. Binding domain mapping
SG11201505856TA (en) 2013-03-14 2015-08-28 Daiichi Sankyo Co Ltd Novel binding proteins for pcsk9
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
US10927154B2 (en) 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CA2949405C (en) 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
DE102014011653A1 (de) * 2014-06-20 2015-12-24 Ulrich Loos Nachweis von Autoantikörpern gegen den TSH-Rezeptor
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
RU2720688C2 (ru) 2015-01-28 2020-05-12 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые белки, специфические в отношении ангиогенеза
AU2016221816B2 (en) 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
AU2016258952C1 (en) 2015-05-04 2020-12-24 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
RU2754466C2 (ru) 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
ES2983910T3 (es) 2015-05-19 2024-10-28 Univ Yale Composiciones para tratar afecciones patológicas de calcificación y métodos que usan las mismas
EP3115371A1 (de) 2015-07-07 2017-01-11 Sanofi Fusionsmoleküle
CA2988831A1 (en) 2015-07-15 2017-01-19 Pieris Pharmaceuticals Gmbh Novel proteins specific for lag-3
CN108699162A (zh) 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
RU2019122482A (ru) 2017-01-18 2021-02-19 Пирис Фармасьютикалс Гмбх Мутеины липокалина с аффинностью связывания в отношении lag-3
LT3830120T (lt) 2018-07-31 2023-07-10 Pieris Pharmaceuticals Gmbh Naujas sulietas baltymas specifinis cd137 ir pd-l1 atžvilgiu
IL284687B2 (en) 2019-02-26 2025-11-01 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
CN116249709A (zh) 2020-06-05 2023-06-09 皮里斯制药有限公司 靶向4-1bb的多聚体免疫调节剂
CA3214220A1 (en) 2021-04-08 2022-10-13 Marina PAVLIDOU Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2024064713A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0079739A3 (de) * 1981-11-12 1984-08-08 The Upjohn Company Auf Albumin basierende Nukleotiden, ihre Replikation und Verwendung und Plasmide zur Verwendung darin
DE3381090D1 (de) 1982-05-19 1990-02-15 Gist Brocades Nv Klonierungssystem fuer kluyveromyce spezies.
FR2532656B2 (fr) 1982-06-02 1985-10-18 Elf Bio Rech Nouveau vecteur de clonage et d'expression, levure et bacterie transformees par ce vecteur
FR2579223B1 (fr) 1985-03-25 1988-12-09 Genetica Procede de preparation microbiologique de la serum-albumine humaine
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
FI870103A7 (fi) 1986-01-13 1987-08-01 Genex Corp Ihmisen seerumin albumiinin tuottaminen Bacillus-kannassa.
FR2594846B1 (fr) 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
IT1203758B (it) * 1986-03-27 1989-02-23 Univ Roma Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
GB8620926D0 (en) * 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
FI107939B (fi) * 1987-07-28 2001-10-31 Dsm Nv Kluyveromyces isäntäkantana
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
IL89992A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
CA2017176A1 (en) * 1989-05-22 1990-11-22 Yoshitomi Pharmaceutical Industries Ltd. Albumin gene-containing plasmid, transformant carrying same, production of such transformant and production of albumin

Also Published As

Publication number Publication date
JPH02276589A (ja) 1990-11-13
FR2649991B2 (fr) 1994-03-04
EP0361991B1 (de) 1999-12-15
HUT51329A (en) 1990-04-28
FI893702L (fi) 1990-02-06
KR910004800A (ko) 1991-03-29
PT91381A (pt) 1990-03-08
FI893702A0 (fi) 1989-08-04
NO893149D0 (no) 1989-08-03
EP0361991A2 (de) 1990-04-04
FI893702A7 (fi) 1990-02-06
AU623425B2 (en) 1992-05-14
NO893149L (no) 1990-02-06
JP3068139B2 (ja) 2000-07-24
NZ230229A (en) 1991-07-26
DE68929115T2 (de) 2000-06-15
DK383189A (da) 1990-02-06
PT91381B (pt) 1995-05-31
DK175846B1 (da) 2005-03-29
FR2649991A2 (fr) 1991-01-25
EP0361991A3 (de) 1992-10-14
DE68929115D1 (de) 2000-01-20
DK383189D0 (da) 1989-08-04
AU3933289A (en) 1990-02-08

Similar Documents

Publication Publication Date Title
DE68929115D1 (de) Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe
AU6733487A (en) Mammalian interleukin-4
CA2113712A1 (en) Papilloma virus vaccine
DE68928380D1 (de) Expression von menschlichen Serumalbumin in methylotrophischen Hefen
ATE70455T1 (de) Verfahren zur reinigung von serumalbumin.
DE3851289D1 (de) Verfahren zur Züchtung rekombinanter Zellen.
DE3773963D1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
PH25249A (en) Method for producing hepatitis b virus proteins in yeast
EP0341746A3 (de) Expression von Hepatitis B S und preS2 Proteinen in methylotrophen Hefen
ZA895821B (en) Method for the microbiological preparation of human serum albumin and other heterologous proteins from a yeast
EP0293827A3 (de) Probe für Leishmaniosis
AU616667B2 (en) Monoclonal antibodies against e7 protein of human type 16 papillomavirus, a process for their preparation, and their use
ATE125298T1 (de) Verfahren zur herstellung von motilinähnlichen polypeptiden und seine expression.
DE68925044D1 (de) Herstellung von Fusionsproteinen oder -polypeptiden
DE3882154D1 (de) Verfahren zur herstellung des pres 1/s2/s-hepatitis-b-antigens aus hefe.
AU4504793A (en) Method for preparing membrane proteins and preserving their oligomeric structures under denaturing conditions, and uses of said proteins in diagnostics and vaccination
ATE92962T1 (de) Mikrobiologisches verfahren zur gewinnung eines proteins durch zuechtung eines mutanten bakterienstammes.
DE69233206D1 (de) Methode zur herstellung rekombinanter proteine und dafür verwendete wirtszellen